Safety Alerts
Updates on impurities in ranitidine products
Audiences
Consumer
Healthcare professional
Industry member
Product type
Therapeutic Products
2 October 2019
This article has been migrated from an earlier version of the site and may display formatting inconsistencies.
HSA would like to update the public on our actions and investigations into the contamination of ranitidine products with a nitrosamine impurity, N-Nitrosodimethylamine (NDMA). Ranitidine is a medicine used to reduce the production of acid in the stomach in patients with conditions such as heartburn and gastric ulcers. Please refer below for the latest updates.
Table caption
Types of communication | Date of release | Title |
|---|---|---|
HSA Update 1 | 16 Sep 2019 | HSA stops supply of eight brands of ranitidine products in Singapore |
Testing methods for NDMA in ranitidine products
This section features test methods developed by the Health Sciences Authority for the identification and determination of a nitrosamine impurity, N-nitrosodimethylamine (NDMA) in ranitidine products.
The testing methods below provide options and guidance for the industry to detect NDMA in ranitidine products. These methods should be validated by users to ensure they are fit for their intended use.
Table caption
Date of release | Title |
|---|---|
1 March 2021 |